

5.60.040

---

|                    |                              |                              |                  |
|--------------------|------------------------------|------------------------------|------------------|
| <b>Section:</b>    | Prescription Drugs           | <b>Effective Date:</b>       | January 1, 2024  |
| <b>Subsection:</b> | Central Nervous System Drugs | <b>Original Policy Date:</b> | October 11, 2019 |
| <b>Subject:</b>    | Abilify Mycite               | <b>Page:</b>                 | 1 of 5           |

---

**Last Review Date:** December 8, 2023

---

## Abilify Mycite

### Description

#### Abilify Mycite (aripiprazole tablets with sensor)

#### Background

Abilify Mycite is a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion. Aripiprazole's mechanism of action is unknown. However, the efficacy of aripiprazole could be mediated through a combination of partial agonist activity at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors and antagonist activity at 5-HT<sub>2A</sub> receptors (1).

The Abilify Mycite System is composed of the following components:

- Aripiprazole tablet embedded with IEM sensor (Abilify Mycite).
- Mycite Patch (wearable sensor) that detects the signal from the IEM sensor after ingestion and transmits data to a smartphone.
- Mycite App – a smartphone application which is used with a compatible smartphone to display information for the patient.
- Web-based portal for healthcare professionals and caregivers.

#### Regulatory Status

FDA-approved indications: Abilify Mycite is indicated for the: (1)

- Treatment of adults with schizophrenia
- Treatment of bipolar I disorder
  - Acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate

---

|                    |                              |                              |                  |
|--------------------|------------------------------|------------------------------|------------------|
| <b>Section:</b>    | Prescription Drugs           | <b>Effective Date:</b>       | January 1, 2024  |
| <b>Subsection:</b> | Central Nervous System Drugs | <b>Original Policy Date:</b> | October 11, 2019 |
| <b>Subject:</b>    | Abilify Mycite               | <b>Page:</b>                 | 2 of 5           |

---

- Maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate
- Adjunctive treatment of adults with Major Depressive Disorder (MDD)

Limitations of Use: The ability of the Abilify Mycite to improve patient compliance or modify aripiprazole dosage has not been established. The use of Abilify Mycite to track drug ingestion in “real-time” or during an emergency is not recommended because detection may be delayed or not occur (1).

Abilify Mycite carries a boxed warning on the risk of increased mortality in elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Mycite is not approved for the treatment of patients with dementia-related psychosis (1).

Abilify Mycite also carries a boxed warning on the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Patients should be monitored closely for worsening and emergence of suicidal thoughts and behaviors (1).

Abilify Mycite should be discontinued in case of severe neutropenia (absolute neutrophil count <1000/mm<sup>3</sup>), tardive dyskinesia if clinically appropriate, and neuroleptic malignant syndrome (1).

Abilify Mycite should be used with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold (1).

Safety and effectiveness of Abilify Mycite in pediatric patients less than 18 years of age have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients (1).

---

#### Related policies

Lybalvi, Zyprexa Relprevv

#### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Abilify Mycite may be considered **medically necessary** if the conditions indicated below are met.

---

|                    |                              |                              |                  |
|--------------------|------------------------------|------------------------------|------------------|
| <b>Section:</b>    | Prescription Drugs           | <b>Effective Date:</b>       | January 1, 2024  |
| <b>Subsection:</b> | Central Nervous System Drugs | <b>Original Policy Date:</b> | October 11, 2019 |
| <b>Subject:</b>    | Abilify Mycite               | <b>Page:</b>                 | 3 of 5           |

---

Abilify Mycite may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Schizophrenia
2. Bipolar I disorder
3. Major depressive disorder (MDD) as adjunctive treatment

**AND ALL** of the following:

- a. Inadequate treatment response to Abilify (aripiprazole) due to non-compliance
- b. Inadequate treatment response, intolerance, or contraindication to a long-acting injectable antipsychotic
- c. Monthly monitoring via the portal by the prescriber and/or designated person(s)
- d. Prescriber agrees to monitor for neuroleptic malignant syndrome and for increased risk of suicidal thoughts and behaviors
- e. **NO** dementia-related psychosis

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Schizophrenia
2. Bipolar I disorder
3. Major depressive disorder (MDD) as adjunctive treatment

**AND ALL** of the following:

---

|                    |                              |                              |                  |
|--------------------|------------------------------|------------------------------|------------------|
| <b>Section:</b>    | Prescription Drugs           | <b>Effective Date:</b>       | January 1, 2024  |
| <b>Subsection:</b> | Central Nervous System Drugs | <b>Original Policy Date:</b> | October 11, 2019 |
| <b>Subject:</b>    | Abilify Mycite               | <b>Page:</b>                 | 4 of 5           |

---

- a. Monthly monitoring via the portal by the prescriber and/or designated person(s)
- b. Prescriber agrees to monitor for neuroleptic malignant syndrome and for increased risk of suicidal thoughts and behaviors
- c. **NO** dementia-related psychosis

### Policy Guidelines

#### Pre - PA Allowance

None

#### Prior - Approval Limits

**Quantity** 90 tablets per 90 days

**Duration** 12 months

#### Prior – Approval *Renewal* Limits

Same as above

### Rationale

#### Summary

Abilify Mycite is a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion. Aripiprazole's mechanism of action is thought to be due to a combination of partial agonist activity at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors and antagonist activity at 5-HT<sub>2A</sub> receptors. Safety and effectiveness of Abilify Mycite in pediatric patients less than 18 years of age have not been established.

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Abilify Mycite while maintaining optimal therapeutic outcomes.

#### References

1. Abilify Mycite [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; November 2022.

### Policy History

# 5.60.040

---

|                    |                              |                              |                  |
|--------------------|------------------------------|------------------------------|------------------|
| <b>Section:</b>    | Prescription Drugs           | <b>Effective Date:</b>       | January 1, 2024  |
| <b>Subsection:</b> | Central Nervous System Drugs | <b>Original Policy Date:</b> | October 11, 2019 |
| <b>Subject:</b>    | Abilify Mycite               | <b>Page:</b>                 | 5 of 5           |

---

| Date           | Action  |
|----------------|---|
| October 2019   | Addition to PA  |
| December 2019  | Annual review   |
| December 2020  | Annual review and reference update                                    |
| March 2021     | Annual editorial review and reference update                          |
| December 2021  | Annual review   |
| March 2022     | Annual review   |
| March 2023     | Annual review and reference update. Changed policy number to 5.60.040 |
| September 2023 | Annual review   |
| December 2023  | Annual review   |

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 8, 2023 and is effective on January 1, 2024.**